The aim of these treatments is to reduce hyperglycemia by activating the endogenous secretion of insulin with sulphonylureas and glitinides or by improving the sensitivity of target tissues to insulin with thiazolidinediones and biguanides [8]. This evidence concerns the gene INS and Hyperglycemia.